Therapy Areas: Vaccines
Medigen's COVID-19 MVC-COV1901 vaccine successfully reviewed and published in The Lancet Respiratory Medicine
18 October 2021 -

Biopharmaceutical company Medigen Vaccine Biologics Corporation on Friday published data from its MVC-COV1901 vaccine phase 2 clinical trial demonstrating promising immunogenicity and safety profiles at The Lancet Respiratory Medicine, a peer-reviewed medical journal.

The company said the results from the MVC-COV1901 vaccine phase 2 clinical trial served as the basis for immunobriding that gives the MVC-COV1901 vaccine's Emergency Use Authorization in Taiwan and can support the advancement in subsequent developments.

This study, which was carried out between 30 December 2020 and 2 April 2021, screened 3854 individuals and randomly assigned (6:1) to the MVC-COV1901 group, or the placebo group. Eligible participants were healthy adults aged 20 years or older. Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart, stated the company.

Based on the wild-type SARS-CoV-2 GMT, the seroconversion rate in the MVC-COV1901 group on day 57 was 99·8%. In both younger and older adults who received the vaccine, almost all participants had seroconversion in younger adults and 99·5% in older adults. One of the most distinct findings in the safety profile is the extremely low incidence of fever, announced the company.

In conjunction with the company's study, the interim analysis showed the MVC-COV1901 vaccine has good safety profile and elicits promising neutralising antibody titres. MVC-COV1901 is safe, well tolerated and rarely causes febrile reactions in both young and older adults. It induces high neutralising antibody and anti-spike IgG titres and it has a seroconversion rate of almost 100% by day 57.